Key result
Hydrochlorothiazide therapy was not associated with a difference in short-term recurrence of atrial fibrillation after catheter ablation compared to matched controls.
Why the study?
Hypokalemia is linked to arrhythmias, but its association with AF is not well studied, prompting evaluation of whether hypokalemia-associated HCT therapy impacts early AF recurrence after RF ablation.
Does hydrochlorothiazide therapy affect early recurrence of atrial fibrillation in patients undergoing radiofrequency catheter ablation?
Observational (n=807)
Does hydrochlorothiazide therapy affect early recurrence of atrial fibrillation in patients undergoing radiofrequency catheter ablation?
Hydrochlorothiazide therapy, despite being associated with slightly lower serum potassium levels, does not increase the risk of early atrial fibrillation recurrence after radiofrequency catheter ablation.
Answers are grounded in this paper and cite their sources.
No support for altering hydrochlorothiazide use around ablation to affect early AF recurrence; leaves open need for randomized confirmation.
BACKGROUND: Hypokalemia has been linked to electrocardiogram changes and afterdepolarization-mediated arrhythmias. However, the association between hypokalemia and atrial fibrillation (AF) has not been well studied. Hydrochlorothiazide (HCT) diuretic therapy was shown to be associated with hypokalemia in multiple studies. We aimed to determine whether HCT therapy is associated with early recurrence of AF after radiofrequency (RF) catheter ablation during a 3-month follow-up. METHODS: We performed a retrospective registry analysis of our internal AF ablation registry, containing 807 consecutive patients that underwent RF ablation for symptomatic AF. Propensity score matching was used to match 156 patients on HCT therapy with 156 controls. Furthermore, we performed propensity score matching between the first and the fourth quartile of baseline serum potassium (K) concentrations in the initial population (N.=807). RESULTS: We observed a small but statistically significant difference in baseline mean potassium levels between the HCT group and the control group (4.03 mmol/L vs. 4.19 mmol/L respectively, P=0.001). There was no difference in short term recurrence of atrial fibrillation in the HCT group compared to the propensity score matched control group (41.0% [N.=64] vs. 45.5% [N.=71], P=0.424). In the comparison between the first and the fourth quartile of baseline serum potassium values, no difference in AF recurrence (38.2% [N.=63] vs. 37.0% [N.=61], P=0.820) during a 3-month follow-up after ablation was observed between both groups. CONCLUSIONS: Patients on HCT therapy showed no difference in short term recurrence of AF after ablation compared to propensity matched controls.
No takes yet. Share an insight, caveat, or question.
Filipovic et al. (2021) conducted an observational in symptomatic atrial fibrillation (n=807). Hydrochlorothiazide (HCT) therapy vs. Propensity score matched controls was evaluated on short term recurrence of atrial fibrillation (p=0.424). Hydrochlorothiazide therapy was not associated with a difference in short-term recurrence of atrial fibrillation after catheter ablation compared to matched controls.
Synapse has enriched 10 related papers. Consider them for comparative context: